(Q46093830)

English

A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03.

scientific article published in September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

Francesco Bertoni

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

F Hitz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

G Martinelli

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

R von Moos

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

W Mingrone

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

M Simcock

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

J Peterson

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

S B Cogliatti

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

D R Zimmermann

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

M Ghielmini

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Hematological Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

154-159

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

21 January 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine for relapsed or resistant lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

7 January 2021

based on heuristic

inferred from DOI database lookup

IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.891

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HON.891

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19274614%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46093830&oldid=1521072251"